Adjuvant icotinib versus observation in patients with completely resected EGFR-mutated stage IB NSCLC (GASTO1003, CORIN): a randomised, open-label, phase 2 trial

BACKGROUND: This phase 2 trial aimed to compare adjuvant icotinib with observation in patients with epidermal growth factor receptor (EGFR) mutation-positive resected stage IB non-small cell lung cancer (NSCLC). METHODS: We performed a randomised, open-label, phase 2 trial from May 1, 2015 to Decemb...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, Wei, Li, Ning, Wang, Bao-Xiao, Zhu, Teng-Fei, Shen, Zhi-Lin, Wang, Tao, Chang, Wu-Guang, Chang, Zeng-Hao, Hu, Xin-Xin, Pu, Yue, Ding, Lie-Ming, Wang, Si-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932314/
https://www.ncbi.nlm.nih.gov/pubmed/36816343
http://dx.doi.org/10.1016/j.eclinm.2023.101839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932314/
https://www.ncbi.nlm.nih.gov/pubmed/36816343
http://dx.doi.org/10.1016/j.eclinm.2023.101839

Ejemplares similares